Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic and sociodemographic factors associated with trajectories of physical and mental health multimorbidity in a South Asian cohort in the UK: A multistate modelling analysis.

PLoS medicine·2026

Same author

Trajectories of child emotional and behavioural difficulties before and during the COVID-19 pandemic in a longitudinal UK cohort.

JCPP advances·2026

Same author

Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care.

Nature medicine·2026

Same author

Combining polygenic risk scores to understand genetic liability to physical-mental health multimorbidity in UK Biobank.

Human molecular genetics·2026

Same author

Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.

European heart journal·2026

Same author

Extreme heat impacts on daily life and adaptive behaviours captured through lived experience.

Environmental research letters : ERL [Web site]·2026

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Using inactivating mutations to provide insight into drug action.

Laura J Corbin¹, Nicholas J Timpson¹

¹MRC Integrative Epidemiology Unit (IEU), University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN UK.

Genome Medicine

|January 29, 2015

Summary

Genetic variation in the NPC1L1 gene supports targeting its protein to reduce coronary heart disease risk. This study validates NPC1L1 as a therapeutic target using a genocopy approach.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Related Experiment Videos

Last Updated: Apr 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Area of Science:

Cardiovascular Medicine
Genetics
Pharmacology

Background:

Ezetimibe effectively lowers plasma cholesterol, but its clinical benefit remains debated.
The NPC1-like 1 (NPC1L1) gene encodes a protein involved in cholesterol absorption.
Genetic variation offers insights into drug target validation.

Purpose of the Study:

To investigate the clinical utility of pharmacologic inhibition of NPC1L1.
To validate NPC1L1 as a therapeutic target for reducing coronary heart disease (CHD) risk.
To apply the concept of genocopy for population-based validation.

Main Methods:

Utilizing naturally occurring genetic variations within the NPC1L1 gene.
Analyzing the association between NPC1L1 genetic variants and CHD risk.
Applying a genocopy approach for therapeutic target validation.

Main Results:

Demonstrated that genetic variation in NPC1L1 is associated with reduced CHD risk.
Provided evidence supporting the role of NPC1L1 in cardiovascular health.
Validated NPC1L1 as a druggable target for cardiovascular disease prevention.

Conclusions:

Pharmacologic inhibition of NPC1L1 holds potential for reducing coronary heart disease risk.
The study validates NPC1L1 as a significant therapeutic target.
Genocopy approach provides a robust method for validating drug targets in a population setting.